Literature DB >> 17297300

Targeting PECAM-1 for anti-cancer therapy.

Horace M Delisser1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17297300     DOI: 10.4161/cbt.6.1.3827

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


× No keyword cloud information.
  6 in total

1.  CD44: target for antiangiogenesis therapy.

Authors:  Horace M DeLisser
Journal:  Blood       Date:  2009-12-10       Impact factor: 22.113

2.  Angiogenesis in platelet endothelial cell adhesion molecule-1-null mice.

Authors:  Gaoyuan Cao; Melane L Fehrenbach; James T Williams; Jeffrey M Finklestein; Jing-Xu Zhu; Horace M Delisser
Journal:  Am J Pathol       Date:  2009-07-02       Impact factor: 4.307

3.  Bimetallic titanocene-gold phosphane complexes inhibit invasion, metastasis, and angiogenesis-associated signaling molecules in renal cancer.

Authors:  Benelita T Elie; Jacob Fernández-Gallardo; Natalia Curado; Mike A Cornejo; Joe W Ramos; María Contel
Journal:  Eur J Med Chem       Date:  2018-10-17       Impact factor: 6.514

4.  Inhibition of lung tumor growth in nude mice by siRNACD31 targeting PECAM-1.

Authors:  Jin-Sheng Ouyang; Yu-Ping Li; Cheng-Shui Chen; Jun-Jie Chen; Tong-Ke Chen; Chang Cai; Li Yang
Journal:  Oncol Lett       Date:  2014-04-25       Impact factor: 2.967

5.  Adjusted CT Image-Based Radiomic Features Combined with Immune Genomic Expression Achieve Accurate Prognostic Classification and Identification of Therapeutic Targets in Stage III Colorectal Cancer.

Authors:  Yi-Ching Huang; Yi-Shan Tsai; Chung-I Li; Ren-Hao Chan; Yu-Min Yeh; Po-Chuan Chen; Meng-Ru Shen; Peng-Chan Lin
Journal:  Cancers (Basel)       Date:  2022-04-08       Impact factor: 6.575

6.  Meta-analysis of global and high throughput public gene array data for robust vascular gene expression discovery in chronic rhinosinusitis: Implications in controlled release.

Authors:  Nitish Khurana; Abigail Pulsipher; Hamidreza Ghandehari; Jeremiah A Alt
Journal:  J Control Release       Date:  2020-11-02       Impact factor: 9.776

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.